884001-10-9

Basic information

• Product Name: 3-(4-Cyanotetrahydro-2H-pyran-4-yl)benzoic acid
• Synonyms: 3-(4-Cyanotetrahydro-2H-pyran-4-yl)benzoic acid
• CAS NO: 884001-10-9
• Molecular Formula: C₁₃H₁₃NO₃
• Molecular Weight: 231
• Mol File: 884001-10-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 468.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.27
• PKA: 4.20±0.10(Predicted)
• CAS DataBase Reference: 3-(4-Cyanotetrahydro-2H-pyran-4-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Cyanotetrahydro-2H-pyran-4-yl)benzoic acid(884001-10-9)
• EPA Substance Registry System: 3-(4-Cyanotetrahydro-2H-pyran-4-yl)benzoic acid(884001-10-9)

Safety Data

• Hazardous Substances Data: 884001-10-9(Hazardous Substances Data)

Upstream product

• 884000-92-4 methyl 3-(4-cyanotetrahydro-2H-pyran-4-yl)benzoate 
• 68432-92-8 methyl 3-cyanomethylbenzoate 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 

Relevant articles and documents

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

QUINOXALINES AS B RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.